[1]
Miller SA, St Onge EL, Whalen KL. Romosozumab: A Novel Agent in the Treatment for Postmenopausal Osteoporosis. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians. 2021 Feb:37(1):45-52. doi: 10.1177/8755122520967632. Epub 2020 Oct 23
[PubMed PMID: 34752536]
[2]
McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG. Romosozumab in postmenopausal women with low bone mineral density. The New England journal of medicine. 2014 Jan 30:370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub 2014 Jan 1
[PubMed PMID: 24382002]
[3]
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. The New England journal of medicine. 2016 Oct 20:375(16):1532-1543
[PubMed PMID: 27641143]
[4]
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. The New England journal of medicine. 2017 Oct 12:377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11
[PubMed PMID: 28892457]
[5]
Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet (London, England). 2017 Sep 30:390(10102):1585-1594. doi: 10.1016/S0140-6736(17)31613-6. Epub 2017 Jul 26
[PubMed PMID: 28755782]
Level 1 (high-level) evidence
[6]
Kerschan-Schindl K. Romosozumab: a novel bone anabolic treatment option for osteoporosis? Wiener medizinische Wochenschrift (1946). 2020 Apr:170(5-6):124-131. doi: 10.1007/s10354-019-00721-5. Epub 2019 Dec 19
[PubMed PMID: 31858345]
[7]
Hsu CP, Maddox J, Block G, Bartley Y, Yu Z. Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab. Journal of clinical pharmacology. 2022 Sep:62(9):1132-1141. doi: 10.1002/jcph.2050. Epub 2022 Apr 2
[PubMed PMID: 35304747]
[8]
Hu M, Zhang Y, Guo J, Guo C, Yang X, Ma X, Xu H, Xiang S. Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis. Frontiers in endocrinology. 2023:14():1188969. doi: 10.3389/fendo.2023.1188969. Epub 2023 Jul 12
[PubMed PMID: 37529613]
Level 1 (high-level) evidence
[9]
Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, Shamliyan T, Cooney TG, Clinical Guidelines Committee of the American College of Physicians, Cross JT Jr, Fitterman N, Lin JS, Maroto M, Obley AJ, Tice JA, Tufte JE. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Annals of internal medicine. 2023 Feb:176(2):224-238. doi: 10.7326/M22-1034. Epub 2023 Jan 3
[PubMed PMID: 36592456]
[10]
Prather C, Adams E, Zentgraf W. Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2020 Nov 16:77(23):1949-1956. doi: 10.1093/ajhp/zxaa285. Epub
[PubMed PMID: 32880646]
[11]
Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. The Journal of clinical endocrinology and metabolism. 2018 Sep 1:103(9):3183-3193. doi: 10.1210/jc.2017-02163. Epub
[PubMed PMID: 29931216]
Level 1 (high-level) evidence
[12]
Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C, Jang G. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. Journal of clinical pharmacology. 2014 Feb:54(2):168-78. doi: 10.1002/jcph.239. Epub 2013 Dec 11
[PubMed PMID: 24272917]
Level 1 (high-level) evidence
[13]
Wu D, Li L, Wen Z, Wang G. Romosozumab in osteoporosis: yesterday, today and tomorrow. Journal of translational medicine. 2023 Sep 27:21(1):668. doi: 10.1186/s12967-023-04563-z. Epub 2023 Sep 27
[PubMed PMID: 37759285]
[14]
Beaudart C, Demonceau C, Sabico S, Veronese N, Cooper C, Harvey N, Fuggle N, Bruyère O, Rizzoli R, Reginster JY. Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis. Aging clinical and experimental research. 2023 Sep:35(9):1789-1806. doi: 10.1007/s40520-023-02478-9. Epub 2023 Jul 3
[PubMed PMID: 37400668]
Level 1 (high-level) evidence
[15]
Kobayashi T, Hara M, Shimanoe C, Morimoto T, Masaaki M, Ito K, Shimazaki T. Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials. Journal of bone and mineral metabolism. 2024 Jul 8:():. doi: 10.1007/s00774-024-01531-5. Epub 2024 Jul 8
[PubMed PMID: 38977437]
Level 1 (high-level) evidence
[16]
Crack LE, Simonian N, Schnitzer TJ, Edwards WB. Monthly treatment with romosozumab for 1 year increases bone mineral at the hip, but not the knee, in women with chronic spinal cord injury. JBMR plus. 2024 Jul:8(7):ziae077. doi: 10.1093/jbmrpl/ziae077. Epub 2024 Jun 7
[PubMed PMID: 38911320]
[17]
McClung MR. Romosozumab for the treatment of osteoporosis. Osteoporosis and sarcopenia. 2018 Mar:4(1):11-15. doi: 10.1016/j.afos.2018.03.002. Epub 2018 Mar 27
[PubMed PMID: 30775535]
[19]
Baek KH, Chung YS, Koh JM, Kim IJ, Kim KM, Min YK, Park KD, Dinavahi R, Maddox J, Yang W, Kim S, Lee SJ, Cho H, Lim SK. Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study. Endocrinology and metabolism (Seoul, Korea). 2021 Feb:36(1):60-69. doi: 10.3803/EnM.2020.848. Epub 2021 Feb 24
[PubMed PMID: 33677928]
Level 1 (high-level) evidence
[20]
. Romosozumab for osteoporosis. Australian prescriber. 2021 Jun:44(3):109-110. doi: 10.18773/austprescr.2021.021. Epub 2021 Apr 20
[PubMed PMID: 34211250]
[21]
Sabaghian T, Delkash P, Rahmannia M, Shahidi Bonjar AH, Centis R, D'Ambrosio L, Sotgiu G, Nasiri MJ, Migliori GB. Efficacy and Safety of Anti-Osteoporotic Agents across CKD Stages: A Meta-Analysis of Randomized Clinical Trials. Kidney & blood pressure research. 2024:49(1):581-587. doi: 10.1159/000540235. Epub 2024 Jul 22
[PubMed PMID: 38972312]
Level 1 (high-level) evidence
[22]
Inose H, Kato T, Tomizawa S, Ariga A, Motoyoshi T, Fukushima K, Takahashi K, Yoshii T, Okawa A. Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: A multicenter retrospective study. Bone reports. 2022 Dec:17():101635. doi: 10.1016/j.bonr.2022.101635. Epub 2022 Nov 7
[PubMed PMID: 36389625]
Level 2 (mid-level) evidence
[23]
Nealy KL, Harris KB. Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis. The Annals of pharmacotherapy. 2021 May:55(5):677-686. doi: 10.1177/1060028020952764. Epub 2020 Aug 29
[PubMed PMID: 32862655]
[24]
Ahdi HS, Wichelmann TA, Pandravada S, Ehrenpreis ED. Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS). BMC pharmacology & toxicology. 2023 Mar 6:24(1):15. doi: 10.1186/s40360-023-00657-y. Epub 2023 Mar 6
[PubMed PMID: 36879299]
Level 3 (low-level) evidence
[25]
Trepanowski N, Yim RM, Wetstone R, MacDonald E, Servattalab S, Jacob-George S, Harris JE. Vitiligo progression in a patient undergoing romosozumab treatment for osteoporosis. JAAD case reports. 2023 Dec:42():26-30. doi: 10.1016/j.jdcr.2023.09.033. Epub 2023 Oct 11
[PubMed PMID: 37965188]
Level 3 (low-level) evidence
[26]
Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE EXECUTIVE SUMMARY. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2020 May:26(5):564-570. doi: 10.4158/GL-2020-0524. Epub
[PubMed PMID: 32427525]
Level 1 (high-level) evidence
[27]
Chouinard L, Felx M, Mellal N, Varela A, Mann P, Jolette J, Samadfam R, Smith SY, Locher K, Buntich S, Ominsky MS, Pyrah I, Boyce RW. Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study. Regulatory toxicology and pharmacology : RTP. 2016 Nov:81():212-222. doi: 10.1016/j.yrtph.2016.08.010. Epub 2016 Aug 26
[PubMed PMID: 27569204]
[28]
Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, Langdahl BL, Miyauchi A, Oates M, Reid IR, Santiago NR, Vanderkelen M, Wang Z, Yu Z. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2022 Aug:37(8):1437-1445. doi: 10.1002/jbmr.4563. Epub 2022 May 20
[PubMed PMID: 35466448]